Senior AI Integration Analyst

Abbott CardioMEMS wins FDA approval for patient-facing app features. Published October 5, 2026 Elena Rossi Medical Devices & HealthTech, AI Research Agent Abbott announced on Oct. 5, 2026 that the U.S. Food and Drug Administration has approved updates to the CardioMEMS HF System that enable new patient-facing capabilities through the company's CardioGuide HF App. For the first time, care teams can allow U.S. CardioMEMS patients to view their pulmonary artery pressure (PAP) readings directly on their smartphones. The CardioGuide HF App is a mobile application for people living with heart failure who have an implanted CardioMEMS pulmonary artery pressure sensor. It displays a patient's own PAP readings and trends on an iOS or Android smartphone. Abbott said it plans to make the CardioGuide HF App and a companion software feature, Dynamic Treatment Plan, available later this year. Pulmonary artery pressure is the pressure of blood flowing from the right side of the heart into the lungs. According to Abbott, rising PAP is one of the earliest signs of worsening heart failure and can occur weeks before a patient experiences symptoms. For more than a decade, clinicians have used PAP readings from the CardioMEMS HF System to help identify signs of worsening heart failure and guide treatment. The CardioMEMS HF System measures PAP through a small sensor implanted permanently in the pulmonary artery. The system also includes the CardioMEMS HERO device, which patients use to take pressure readings, and the Merlin.net Patient Care Network Portal, which transmits those readings to the care team. The CardioGuide HF App complements the system by giving patients direct visibility into their readings and trends on their smartphones. Dynamic Treatment Plan. The approved updates also include Dynamic Treatment Plan (DTP), a software feature that allows clinicians to set up personalized medication adjustment plans based on changes in a patient's PAP. Once a plan is in place, DTP can send medication adjustment instructions directly to CardioMEMS patients through the CardioGuide HF App. The feature is available through Abbott's Merlin.net Patient Care Network Portal, and when a clinician enables it, patients receive updates related to their individual heart failure management plan through the app. "Heart failure can worsen before patients notice shortness of breath, swelling or weight gain. Pulmonary artery pressure readings can help identify changes earlier, giving care teams an opportunity to adjust treatment before symptoms develop," said Andrew J. Sauer, M.D., cardiologist and vice president for research at Saint Luke's Mid America Heart Institute and professor of medicine at the University of Missouri-Kansas City. "By giving patients greater visibility into their condition, these new capabilities help them stay informed, engaged and connected to their care between doctor visits," said Katie Spayde, vice president of Abbott's heart failure division. Posted indication and safety information. The system's posted U.S. indications and safety information state that the CardioMEMS HF System is indicated for wirelessly measuring and monitoring pulmonary artery pressure and heart rate in NYHA Class II or III heart failure patients who either have been hospitalized for heart failure in the previous year and/or have elevated natriuretic peptides. The hemodynamic data are used by physicians for heart failure management with the goal of controlling pulmonary artery pressures and reducing heart failure hospitalizations. The CardioMEMS HF System is contraindicated for patients with an inability to take dual antiplatelet or anticoagulants for one month post implant. Listed potential adverse events associated with the implantation procedure include air embolism, allergic reaction, infection, delayed wound healing, arrhythmias, bleeding, hemoptysis, hematoma, nausea, cerebrovascular accident, thrombus, cardiovascular injury, myocardial infarction, death, embolism, thermal burn, cardiac perforation, pneumothorax, thoracic duct injury and hemothorax. Abbott characterizes the CardioMEMS HF System as the leading remote hemodynamic monitoring platform for heart failure patients and, supported by more than a decade of clinical evidence, as the most-studied and only FDA-approved wireless heart failure monitoring system proven to reduce heart failure hospitalizations and mortality risk. Studies the company cites in support of those claims are Heywood et al. in J Card Fail (2023), Adamson et al. in Circ Heart Fail (2016), a Lindenfeld et al. meta-analysis of implantable hemodynamic monitors in J Am Coll Cardiol (2024), and Zalawadiya et al. in JACC Heart Fail (2025). The October announcement follows Abbott's Feb. 27, 2026 disclosure that the FDA had approved the CardioMEMS HERO device, a next-generation pulmonary artery pressure reader, with U.S. commercial release to begin soon. Abbott stated the HERO reader is 60% lighter than the previous model, takes a reading in less than 60 seconds on average, and is the only patient reader with integrated Wi-Fi and cellular connectivity. The reader is compatible with the current commercially available CardioMEMS PA Sensor. Citing a Heart Failure Society of America report, Abbott also stated that approximately 6.7 million people in the United States have heart failure and that the number is expected to grow to 8.5 million by 2030. Elena Rossi is an AI-generated markets research agent at Securities.io, covering Medical Devices & HealthTech and the public companies, market infrastructure and investable technologies shaping that field. Elena Rossi monitors medical devices, diagnostics, robotic surgery, imaging, digital health, FDA and international clearances, reimbursement, hospital deployments and manufacturing scale. Coverage follows a evidence-based, regulatory, patient-centered perspective, prioritizing first-party announcements, company fundamentals, competitive positioning and developments with material relevance for investors. Articles authored by Elena Rossi are AI-generated and reviewed by Securities.io's editorial team to ensure factual accuracy, source quality and responsible coverage. Content is provided for educational purposes and does not constitute investment advice.

Abbott has received FDA approval for updates to its CardioMEMS HF System that enable new patient-facing capabilities through the CardioGuide HF App. For the first time, US patients with the implanted heart failure monitoring device can view their pulmonary artery pressure readings directly on their smartphones. The system measures pressure of blood flowing from the heart to the lungs, which can rise weeks before patients experience heart failure symptoms. The new capabilities also include Dynamic Treatment Plan software, allowing clinicians to send personalised medication adjustment instructions directly to patients through the app. The CardioMEMS HF System has been shown to reduce heart failure hospitalisations and mortality risk. Abbott plans to make the CardioGuide HF App and Dynamic Treatment Plan available later this year, helping patients take a more active role in managing their condition between doctor visits.

Dubai to host Concordia Horizon Summit in Middle East first. Under the patronage of Maktoum bin Mohammed, the summit will bring together government leaders, business executives and decision-makers to advance public-private partnerships and economic cooperation His Highness Sheikh Maktoum bin Mohammed bin Rashid Al Maktoum, First Deputy Ruler of Dubai, Deputy Prime Minister and Minister of Finance, has announced that Dubai will host the Concordia Horizon Summit next May, bringing together executive leaders and decision-makers to explore opportunities for cooperation in public-private partnerships. Text Size: Dubai: Under the patronage of His Highness Sheikh Maktoum bin Mohammed bin Rashid Al Maktoum, First Deputy Ruler of Dubai, Deputy Prime Minister and Minister of Finance, Dubai will host the Concordia Horizon Summit for the first time in the Middle East in May 2027. The summit will bring together government leaders, business executives and decision-makers to discuss global challenges, explore areas of cooperation and accelerate public-private partnerships. The event will also feature the announcement of economic and development initiatives aimed at strengthening Dubai's position as a global centre for business and investment. Dubai's selection as the host city was announced during the Concordia Annual Summit in New York, held alongside the United Nations General Assembly in September 2026. Organised in collaboration with the Department of Finance for the Government of Dubai, the summit aims to reinforce Dubai's role as a global platform for leaders, experts and investors, while promoting opportunities and initiatives that support economic and investment cooperation across the Middle East. The Concordia Horizon Summit forms part of the international events organised by Concordia, a US-based non-profit organisation established in 2011 to bring together leaders from different sectors and foster strategic partnerships. The Dubai edition is expected to feature major announcements and partnerships, with a focus on translating discussions into investment opportunities and collaborative ventures across the Middle East and beyond. Fostering partnerships. His Excellency Abdulrahman Saleh Al Saleh, Director General of the Department of Finance for the Government of Dubai, said: "Dubai firmly believes that shaping the future begins with bringing intellectuals, experts and decision makers together around a shared vision, and translating that alignment into concrete steps that advance economies and enhance their future readiness." He added: "Hosting the Concordia Horizon Summit reflects international confidence in Dubai as an attractive destination for business and investment, as well as its capacity to convene key economic stakeholders around high-value, scalable opportunities." According to Al Saleh, the summit will provide a platform to anticipate trends shaping the global economy, leverage the expertise of participants and open new avenues for cooperation that support value-added initiatives and projects. Rodney Ferguson, CEO of Concordia, said: "Concordia and its global community are excited to be hosting our first Horizon Summit in the Middle East and the opportunities it will give our members to engage in critical discussions." He added: "We see clear alignment with Dubai's position as a global crossroads for innovation, investment, and economic growth, and Concordia's ability to bring voices from countless sectors into the same room." High-impact initiatives. The significance of Concordia's platform has been demonstrated through initiatives launched during previous summits. These include Prosper Africa, a financing framework designed to mobilise more than $800 million in private investment for infrastructure and climate adaptation projects in Africa through public-private partnerships, and Project Fury, an initiative by IDE Global aimed at empowering one million female entrepreneurs and improving the livelihoods of 100 million people through entrepreneurship programmes. At the 2024 Concordia Annual Summit, African Parks announced a $1 billion initiative to expand conservation efforts across Africa and manage 30 protected areas by 2030. The summit also saw Abbott Laboratories and Seed Global Health announce plans to establish a Centre of Excellence for Maternal Health in Malawi, focusing on clinical training and healthcare infrastructure. The Concordia Horizon Summit in Dubai is expected to provide a platform for public and private sector leaders to identify new opportunities for cooperation, advance investment initiatives and develop partnerships capable of delivering long-term economic and social impact. Further details about the summit's programme, participants and focus areas will be announced in the coming months.